Public record
NMN (nicotinamide mononucleotide): the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Product listings
FDA product listings naming NMN (nicotinamide mononucleotide)
The FDA NDC Directory holds 3 listings naming NMN (nicotinamide mononucleotide) from 3 firms: 2 bulk ingredient listings and 1 finished product listing, 0 under an FDA-approved application. A listing is a registration by a firm, not an FDA approval.
| Measure | Value | Note |
|---|---|---|
| Listings naming NMN (nicotinamide mononucleotide) | 3 | |
| Bulk ingredient listings | 2 | raw material registrations, not finished medicines |
| Of those, bulk ingredient for human prescription compounding | 0 | |
| Finished product listings | 1 | |
| Listings under an FDA-approved application | 0 | |
| Firms with a listing | 3 |
How this was calculated
Searched ingredient and product names in the NDC Directory download for the exact name variants, then counted listings by FDA marketing category and by listing firm.
Current NDC Directory listings whose ingredient or product name contains nicotinamide mononucleotide
Firms submit listings themselves. A listing does not mean FDA has reviewed the substance for safety or effectiveness, or that it may lawfully be compounded.
Clinical studies
Registered clinical studies of NMN (nicotinamide mononucleotide)
ClinicalTrials.gov lists 33 registered studies that name NMN (nicotinamide mononucleotide) as an intervention as of 2026-11-11. Of these, 12 are recruiting, 14 are completed and 1 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 33 |
| Recruiting now | 12 |
| Not yet recruiting | 1 |
| Completed | 14 |
| Terminated, withdrawn or suspended | 1 |
| Phase 3 (including phase 2/3) | 1 |
| Phase 2 (including phase 1/2) | 5 |
| Phase 1 | 6 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches nicotinamide mononucleotide, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
Published research
Published papers mentioning NMN (nicotinamide mononucleotide)
PubMed indexes 1,556 papers that mention NMN (nicotinamide mononucleotide) in the title or abstract, 1,036 of them published from 2016 to 2025. The count for 2025 is 188 and for 2024 is 182.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 1,556 | |
| Published 2016 to 2025 | 1,036 | |
| Published in 2025 | 188 | |
| Published in 2024 | 182 | |
| Busiest year since 2016 | 2025 | 188 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'nicotinamide mononucleotide' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
Articles on NMN (nicotinamide mononucleotide)
- NMN Dosing and Evidence: What Clinicians Prescribe
- NMN and NR Dosing: Evidence-Based Protocols for NAD+ Precursors, Rapamycin, and Metformin
- NMN and NR Dosing for Adults 30 to 49: Evidence-Based Protocol Guide
- NMN/NR (Nicotinamide Mononucleotide/Riboside): How to Safely Stop
- NMN and NR: FDA Status and Manufacturing Information
- NMN/NR Mechanism of Action: The Full NAD+ Biosynthesis Pathway Explained